GlassScriptPhysician profile
Glen N Feather
NPI 1962492900
$11,107.77
in general payments reported to CMS, 2019-2025
30 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $227 · 2021: $276 · 2022: $3,969 · 2023: $2,238 · 2024: $2,299 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,227 · Travel and Lodging: $2,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,226.98 |
| Travel and Lodging | $2,147.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,471.22 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Si-Bone, INC. | $1,578.42 | 2019-2025 | |
| Boston Scientific Corporation | $840.06 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $543.58 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $274.08 | 2019-2024 | Ajovy |
| Lundbeck LLC | $212.74 | 2024-2025 | Vyepti |
| Allergan, INC. | $171.07 | 2019-2020 | |
| Lilly USA, LLC | $144.82 | 2019-2022 | |
| Vertiflex, INC. | $116.66 | 2019 | |
| Abbott Laboratories | $101.61 | 2019-2024 | Freestyle Libre 3, Octrode, Eterna |
| Biohaven Pharmaceutical Holding Company LTD. | $62.53 | 2022 | |
| Pfizer INC. | $57.00 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $54.54 | 2019-2020 | |
| Tersera Therapeutics LLC | $52.32 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $47.76 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $47.40 | 2019-2020 | |
| Amgen INC. | $44.15 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.04 | 2019 | |
| Myoscience INC. | $34.28 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $31.94 | 2025 | |
| Zimmer Biomet Holdings, INC. | $29.14 | 2025 | Persona |
| Orexo US, INC. | $23.64 | 2025 | Zubsolv |
| Indivior INC. | $22.03 | 2019 | |
| Biodelivery Sciences International, INC. | $18.76 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.50 | 2023 | Seglentis |
| Corcept Therapeutics | $16.43 | 2022 | |
| Mdd US Operations, LLC | $14.34 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.25 | 2019 | |
| Daiichi Sankyo INC. | $11.85 | 2019 | |
| Collegium Pharmaceutical, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Feather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.